PMID- 25848285
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150407
LR  - 20200930
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 11
DP  - 2015
TI  - Decreased serum levels of brain-derived neurotrophic factor in schizophrenic 
      patients with deficit syndrome.
PG  - 865-72
LID - 10.2147/NDT.S79444 [doi]
AB  - BACKGROUND: Brain-derived neurotrophic factor (BDNF) is a well-established 
      neurotrophin that plays a role in the pathophysiology of numerous psychiatric 
      disorders. Many studies have investigated the serum BDNF levels in patients with 
      schizophrenia. However, there are restricted data in the literature that compare 
      the serum BDNF levels in patients with deficit and nondeficit syndromes. In this 
      study, we aimed to compare the serum BDNF levels between schizophrenic patients 
      with deficit or nondeficit syndrome and healthy controls. METHODS: After 
      fulfilling the inclusion and exclusion criteria, 58 patients with schizophrenia 
      and 36 healthy controls were included in the study. The patients were grouped as 
      deficit syndrome (N=23) and nondeficit syndrome (N=35) according to the Schedule 
      for the Deficit Syndrome. Three groups were compared in terms of the 
      sociodemographic and clinical variants and serum BDNF levels. RESULTS: The groups 
      were similar in terms of age, sex, body mass index, and smoking status. The serum 
      BDNF levels in patients with deficit syndrome were significantly lower than those 
      in healthy controls. In contrast, the serum BDNF levels in patients with 
      nondeficit syndrome were similar to those in healthy controls. CONCLUSION: This 
      study suggests that decreased BDNF levels may play a role in the pathophysiology 
      of schizophrenic patients with deficit syndrome. Nonetheless, additional studies 
      using a larger patient sample size are needed to investigate the serum BDNF 
      levels in schizophrenic patients with deficit syndrome.
FAU - Akyol, Esra Soydas
AU  - Akyol ES
AD  - Deparment of Psychiatry, Yenimahalle Education and Research Hospital, Ankara, 
      Turkey.
FAU - Albayrak, Yakup
AU  - Albayrak Y
AD  - Department of Psychiatry, Faculty of Medicine, Namik Kemal University, Tekirdag, 
      Turkey.
FAU - Beyazyuz, Murat
AU  - Beyazyuz M
AD  - Department of Psychiatry, Biga State Hospital, Canakkale, Turkey.
FAU - Aksoy, Nurkan
AU  - Aksoy N
AD  - Department of Biochemistry, Yenimahalle Education and Research Hospital, Ankara, 
      Turkey.
FAU - Kuloglu, Murat
AU  - Kuloglu M
AD  - Department of Psychiatry, Faculty of Medicine, Akdeniz University, Antalya, 
      Turkey.
FAU - Hashimoto, Kenji
AU  - Hashimoto K
AD  - Division of Clinical Neuroscience, Chiba University Center for Forensic Mental 
      Health, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150330
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4386764
OTO - NOTNLM
OT  - biomarker
OT  - neurotrophin
OT  - psychosis
EDAT- 2015/04/08 06:00
MHDA- 2015/04/08 06:01
PMCR- 2015/03/30
CRDT- 2015/04/08 06:00
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2015/04/08 06:01 [medline]
PHST- 2015/03/30 00:00 [pmc-release]
AID - ndt-11-865 [pii]
AID - 10.2147/NDT.S79444 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2015 Mar 30;11:865-72. doi: 10.2147/NDT.S79444. 
      eCollection 2015.